Case report on JMML evolving to AML in a 14-yearold male acquiring an additional i(X)(q10).
These cells are negative for CD13, CD14, CD15, CD16, CD36, CD61, and CD64. The analysis also identified 7.6% granulocytes. Pathology 4% atypical myeloid blasts (with expression of CD7,CD11b, heterogeneous CD56, heterogeneous HLA-DR and heterogeneous CD38 and lack of CD13) and an increased population of atypical monocytic cells (36%) (with expression of bright CD56, CD117 and heterogeneous HLA-DR). Electron microscopy None Diagnosis Acute myeloid leukemia (AML) arising out of juvenile myelomonocytic leukemia (JMML).
Survival

Treatment
Initially patient was diagnosed with JMML. The splenectomy followed by 2 cycles (28 days each) of low dose chemotherapy (consistent of oral mercaptopurine, cis-retinoic acid, low dose cytarabine). This is followed by allogeneic bone marrow transplant from HLA matched unrelated female donor. Preparative (conditioning) myeloablative regimen performed with busulfan, fludarabine, antithymocyte globulin (ATG) and graft versus host disease prophylaxis with mycophenolate mofetil and tacrolimus. BMT was performed after 2.5 month AIV and neutrophil engraftment was on day +26 and platelet engraftment on day +24 post-transplant. After BMT the patient received multiple courses of different chemotherapy and immunotherapy in order to achieve remission. Secondary AML arising from JMML was diagnosed after 10 month AIV and standard induction chemotherapy for AML was started (A10D3E5 according to COG-AML1031), due to failure to achieve remission status different agents in different combinations were administered including the following: Azacitadine, oral mercaptopurine, decitabine, lenalidomide, cisretinoic acid, low dose cytarabine, high-dose cytarabine and mitoxantrone, hydroxyurea. First i(X)(q10) appearance was recorded after 18 month. Eventually the patient underwent a second bone marrow transplant with a different donor 23 month AIV, conditioning with fludarabine and total body irradiation. He is currently awaiting count recovery. 
Other Molecular Studies
Comments
Here we describe a 14 year old male patient who was initially diagnosed with JMML and a bone marrow JMML evolving to AML in a 14-year-old male acquiring an additional i(X)(q10) Taghiyev AF, et al. Atlas Genet Cytogenet Oncol Haematol. 2016; 20(10) karyotype of (45, XY, (Dewald, GW. et al. 1989 , Byrd, JC. et all 2002 . The most common anomaly is isodicentric X with idic(X)(q13). The i(X)(p10) and i(X)(q10) are observed less frequently. Most isochromosome X, observed in HM are affecting females. The reported cases in males include i(X)(q10) in a 51-year-old man with common ALL (Bacher, U et al. 2009 ), a 57-year-old man with Follicular Lymphoma (Donti, E. et al. 1988 ) and a man with DLBCL of unknown age (Itoyama, T. et al. 2002) .
